Taiwania Capital closes its biotech fund for US$196 million

Taiwania Capital announced today the successful closing of its second fund, Taiwania Capital Buffalo II Bioventures (“Buffalo II”). The fund secured close to NTD 6 billion (US$196 million) in commitment – an oversubscribed fundraise due to great support from investors.

 

Buffalo II will be dedicated to startups in the biotech and healthcare space, with an eye for innovations in drug development, medical device and healthcare services. Managed by veterans in the industry, the fund aims to promote the growth of Taiwan’s biotech and healthcare industry and present Taiwan’s outstanding startups to the world.

 

Buffalo II is the second fund raised by Taiwania Capital within less than one year. Its first fund, Taiwania Capital Buffalo Fund Co., Ltd., primarily invests in the field of IoT and smart machinery and was also well received by a wide array of investors with a total commitment amount of NTD 4.65 billion (US$152 million).